Elucidata
Elucidata provides Polly, an AI-native biomedical data platform that harmonizes multi-modal omics and clinical data into knowledge graphs to help pharmaceutical and biotech companies identify and validate drug targets, serving 90+ biopharma R&D partners.
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Elucidata does
Elucidata is a biomedical data platform company founded in 2015 that delivers ML-ready, curated molecular data to accelerate drug discovery. Its flagship platform, Polly, is a multi-modal agentic stack for target validation that ingests proprietary and public biomedical data, connects evidence through knowledge graphs, scores candidate targets across 14 dimensions, and delivers ranked, decision-ready target shortlists. The platform is modular — comprising Polly Scout (AI-powered public dataset discovery), Atlas (multi-modal data harmonization), Polly Xtract (NLP document processing), Co-Scientist (agentic discovery workflows), Polly Knowledge Graph, Data Concierge, and PollyGPT — and supports cloud, on-premise, or hybrid deployment. A multi-agent AI system for metadata curation achieves 93% recall across 23 metadata fields and outperforms GPT-4.1 on accuracy, F1, and traceability; Elucidata also enables foundation-model fine-tuning such as scGPT for cell-type annotation and batch-effect correction.
The company serves enterprise pharmaceutical companies (Eli Lilly, Bristol Myers Squibb, Pfizer, Janssen, Boehringer Ingelheim, Otsuka, Chugai), biotech firms (Alnylam, Owkin, Atavistik, CTRL Therapeutics, Immutas, Auron, Immunitas, Exelixis), research institutions (Stanford, DeepMind), and emerging biotech, with 90+ biopharma partners and 40+ programs advanced beyond IND. Elucidata earns revenue through annual SaaS subscriptions to Polly, professional services billed as Statements of Work for implementation and custom bioinformatics pipelines, and recurring managed services such as Data Concierge and Metadata Curation. The company runs an enterprise field-sales motion targeting R&D IT leaders and translational scientists at top pharma and biotech firms, with offices in San Francisco (operational HQ), Cambridge (legal HQ), Boston, New Delhi, and Bengaluru. Notable recent moves include the January 2026 launch of AI Labs for biomedical AGI research and a May 2025 biobank partnership with Sapien Biosciences.
Elucidata firmographics
Firmographics- Name
- Elucidata
- Legal name
- Elucidata Corporation
- Website
- https://elucidata.io
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Elucidata provides Polly, an AI-native biomedical data platform that harmonizes multi-modal omics and clinical data into knowledge graphs to help pharmaceutical and biotech companies identify and validate drug targets, serving 90+ biopharma R&D partners.
- Ownership category
- akta.pro rank
Elucidata industry classification
Industry- Product category
- Drug Discovery & Biomedical Data Analytics Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN)
Keywords
Where Elucidata is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Elucidata business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Subscription Services (SaaS): Software subscription services for access to Polly platform. Customers pay subscription fees for platform access during the subscription term. Professional services available for implementation and custom development.
- Professional Services: Software implementation and development services including custom bioinformatics pipelines, data integration, and platform customization. Billed as Statements of Work alongside subscription services.
- Managed Services: Ongoing managed data services including Data Concierge, Metadata Curation, and Data Quality Assessments delivered as recurring services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription with customizable modules and professional services |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels9 records
Elucidata product offering
Product offeringCore offering
Elucidata delivers ML-ready, curated biomedical molecular data and operates Polly, a multi-modal agentic stack for target validation in drug discovery. Polly ingests proprietary and public biomedical data, connects evidence through knowledge graphs, scores target candidates across 14 dimensions, and delivers ranked decision-ready target lists. The platform is supplemented by managed services (Data Concierge, Metadata Curation, Data Quality Assessments, custom bioinformatics pipelines) and supports cloud, on-premise, or hybrid deployment for biopharma R&D teams.
Product overview
Elucidata offers Polly, a Multi-Modal Agentic Stack for Target Validation, designed as a unified platform with modular components for drug discovery. The core Polly platform is supplemented by specialized modules including Polly Scout (public dataset discovery), Polly Atlas (data harmonization), Polly Knowledge Graph (evidence connections), Polly Xtract (document processing), Co-Scientist (agentic workflows), and Data Concierge (data curation). Additional offerings include PollyGPT for natural language querying, Metadata Curation, Data Quality Assessments, Bioinformatics Pipelines, and Custom Apps & Dashboards. The platform supports deployment across cloud, on-premise, or hybrid environments with Security & Compliance controls for regulated R&D. Recent additions include AI Labs for biomedical AGI research and Biologics Data Management for protein-based therapy pipelines.
Differentiator
Problem solved
Functional benefit
Brands
- Polly: Multi-Modal Agentic Stack for Target Validation - AI-powered platform for biomedical data harmonization, knowledge graphs, and drug discovery target identification.
Products and services
- Polly Multi-Modal Agentic Stack for Target Validation that ingests proprietary and public biomedical data, connects it through a knowledge graph, scores candidates across 14 dimensions, and delivers ranked decision-ready target lists. Sold as a SaaS subscription to biopharma R&D teams with cloud, on-premise, or hybrid deployment options.
- AI Labs Initiative for developing advanced AI solutions for biomedical AGI, focusing on out-of-distribution detection and analysis across human, plant, and animal health applications.
- Biologics Data Management (BDM) Scalable biologics inventory data management via hosted platform for managing sequences, physical properties, cell lines, and production runs for protein-based, RNA, lipid, and small molecule therapeutics.
Quantifiable outcome
- 40% reduction in data preparation time for biopharma company
- +7 more outcomes
Companies that use Elucidata
Customer profileNamed customers20 records
Segments5 records
Ideal customer profiles3 records
Elucidata technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability10 records
Feature11 records
Elucidata partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- IDBScoreCross-industry panel participation at IDBS i3 2026 forum in Boston. Elucidata joined IDBS, AWS, and Boehringer Ingelheim to reinforce that reliable AI execution depends on structured, contextualized data foundations and governance.
- AWScoreCross-industry panel participation at IDBS i3 2026 forum. AWS and Elucidata both contributed to discussions on reliable AI execution and structured data foundations for BioPharma.
- Boehringer IngelheimcoreCross-industry panel participation at IDBS i3 2026 forum showcasing real-world outcomes from data-driven BioPharma implementations with measurable operational gains.
- Sapien BiosciencescoreStrategic partnership announced to transform biobank assets into high-quality AI products. Collaboration focuses on converting biobank samples and data into structured, analysis-ready datasets for AI-driven drug discovery.
- Genedata BiologicscoreIntegration partnership for customizing Genedata Biologics for internal processes and instruments. Delivers purpose-built integrations and last-mile customizations eliminating manual data transfer errors.
Scale indicators14 records
Recent moves6 records
Expansion highlights5 records
Elucidata competitors and assessment
Company assessmentBroad incumbents
- Tempus: Tempus builds large-scale multimodal biomedical data libraries and AI models, selling data and tools to biopharma in a category that overlaps Elucidata's multi-omics + clinical data positioning.
- IQVIA: IQVIA is a large life sciences technology and data provider offering R&D informatics, real-world data, and AI tools to pharma — competing with Elucidata for the same enterprise research IT budgets.
- Benchling: Benchling is a widely deployed cloud platform for R&D data, especially in biologics, and competes with Elucidata as the system-of-record for biopharma experimental and molecule data.
- Recursion Pharmaceuticals: Recursion combines high-content biology data with ML for drug discovery at much larger scale and capital intensity, competing for the same enterprise pharma partnerships and AI-drug-discovery narrative.
- Genedata: Genedata provides enterprise R&D informatics platforms including Genedata Biologics, used by top biopharma for biologics data management — directly overlapping Elucidata's Biologics Data Management offering.
Direct peers
- Datavant: Datavant connects and de-identifies health data for research, comparable to Elucidata's multi-modal data harmonization and EHR integration work for biopharma customers.
- Schrödinger: Schrödinger provides computational chemistry and biology software used by pharma for molecular design and target evaluation, overlapping directly with Elucidata's drug discovery software customer base.
- Insitro: Insitro combines ML with biological data for target discovery and drug development, targeting similar biopharma customers and competing for the same platform-of-record position in AI-driven R&D.
- Owkin: Owkin applies AI to biomedical and clinical data for drug discovery and target identification, selling into the same biopharma R&D buyer base as Elucidata and using multi-modal data and federated learning approaches.
- DNAnexus: DNAnexus provides a cloud platform for biomedical data management and analysis, including multi-omics, similar to Elucidata's Polly Atlas and harmonization infrastructure for biopharma R&D.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Elucidata social profiles
Digital presenceElucidata compliance and trust
Trust signalCompliance4 records
Elucidata financial estimates
Financial estimateRevenue estimate
Valuation estimate
Elucidata leadership team
Management profileNumber of profiles
Profiles4 records
Elucidata funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Elucidata M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Elucidata
What does Elucidata do?
Elucidata delivers ML-ready, curated biomedical molecular data and operates Polly, a multi-modal agentic stack for target validation in drug discovery. Polly ingests proprietary and public biomedical data, connects evidence through knowledge graphs, scores target candidates across 14 dimensions, and delivers ranked decision-ready target lists. The platform is supplemented by managed services (Data Concierge, Metadata Curation, Data Quality Assessments, custom bioinformatics pipelines) and supports cloud, on-premise, or hybrid deployment for biopharma R&D teams.
Is Elucidata a public or private company?
Elucidata is a private company. It is classified as venture growth investor backed and is currently operating.
When was Elucidata founded?
Elucidata was founded in 2015. It employs 101 to 250 people.
Where is Elucidata based?
Elucidata is headquartered in Cambridge, United States, in the North America region.
How does Elucidata make money?
Three revenue lines are on record. Subscription Services (SaaS) is the primary driver. The others are professional Services and managed Services.
Who are Elucidata's main competitors?
Broad incumbents on record are Tempus, IQVIA, Benchling, Recursion Pharmaceuticals and Genedata. Direct peers are Datavant, Schrödinger, Insitro, Owkin and DNAnexus.
Does Elucidata have an API?
No public API is recorded for Elucidata.
What industry is Elucidata in?
Elucidata's product category is Drug Discovery & Biomedical Data Analytics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5132 and its SIC code is 7372.